MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from december
2025 public...
$80,964K
Proceeds from exercise of
underwriters option in...
$2,528K
Proceeds from exercise of
stock options
$21K
Proceeds from exercise of
warrants
$1K
Net cash provided by
(used in) financing...
$82,715K
Canceled cashflow
$799K
Net increase
(decrease) in cash and cash...
-$113,141K
Canceled cashflow
$82,715K
Proceeds from maturity
and redemption of...
$65,234K
Stock-based compensation
$3,826K
Operating lease
right-of-use asset
$1,081K
Accrued expenses and
other current...
$821K
Depreciation
$362K
Other assets
-$322K
Offering costs paid in
connection with the...
$614K
Taxes paid related to
net share...
$185K
Net cash provided by
(used in) investing...
-$139,491K
Canceled cashflow
$65,234K
Net cash provided by
(used in) operating...
-$56,365K
Canceled cashflow
$6,412K
Purchase of marketable
debt securities
$204,631K
Purchase of property and
equipment
$94K
Net income (loss)
-$57,439K
Prepaid expenses and
other current assets
$2,087K
Amortization of premium
(accretion of discount) on...
-$1,245K
Operating lease
liabilities
-$1,124K
Accounts payable
-$873K
Realized loss (gain) on
redemption of marketable...
$9K
Back
Back
Cash Flow
source: myfinsight.com
Protara Therapeutics, Inc. (TARA)
Protara Therapeutics, Inc. (TARA)